Inclusion Criteria:

Part A:

1. Patients with refractory or recurrent advanced late stage solid tumors without
available therapeutic options .

Part B, C, D and E:

1. Patients with refractory or recurrent advanced mCRC and wild-type KRAS who have
progressed on EGFR Ab treatment.

2. No more than 4 previous chemotherapy regimens.

3. Patients must be willing to have a biopsy performed from a tumor lesion at screening
and at Visit 6.

Part A, B, C, D and E:

1. Histologically or cytologically confirmed diagnosis of cancer

2. Failure and/or intolerance to standard chemotherapy

3. Life expectancy of at least 3 months

4. ECOG performance status ≤2

Exclusion Criteria:

1. Patients with clinically symptomatic brain metastases.

2. Received the following treatments prior to Visit 2:

- Cytotoxic or cytostatic anti-cancer chemotherapy within 4 weeks

- Total resection or irradiation of the target lesion

- Antibody therapy within 4 weeks and vaccines within 12 weeks

- Tyrosin kinase inhibitors within 4 weeks

- Any investigational agent within 4 weeks

3. Diarrhea CTCAE >1

4. Skin rash CTCAE >1

5. Abnormal organ or bone marrow function.

6. Use of immunosuppressive agents for the past 4 weeks prior to trial start, including
systemic corticosteroids used at doses above 20mg/day of prednisolone or equivalent.

7. History of other malignancy within 5 years prior to trial start, with the exception
of basal cell carcinoma of the skin and carcinoma in situ of the cervix (not in Part
A).

8. Active severe infection, any other concurrent disease or medical conditions that are
deemed to interfere with the conduct of the trial as judged by the investigator.

9. Known HIV positive

10. Known active hepatitis B or C

11. Patients with known uncontrolled allergic conditions or allergy to the study drug
and/or their components.

12. Clinically significant cardiac disease including unstable angina, acute myocardial
infarction within six months from Visit 1, congestive heart failure, and arrhythmia
requiring therapy, with the exception of extra systoles or minor conduction
abnormalities and controlled and well treated chronic atrial fibrillation.

13. Significant concurrent, uncontrolled medical condition evaluated by the investigator
to interfere with effect of the trial drug.